Radha Reddy
Endocrinology, Diabetes & Metabolism · Claremont, CANPI 1780652073
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,013 and has fallen 89.4% since, to $107 in 2025.
Across 87 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$231
- Regeneron Healthcare Solutions, Inc.$176
- Amgen$171
- Dexcom, Inc.$94
- Radius Health, Inc.$90
- Boehringer Ingelheim$74
- plus $798 from 25 others
What the payments were for
- Food & beverage$1,54695%
- Education$885%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $231 |
| Regeneron Healthcare Solutions, Inc. | 5 | $176 |
| Amgen(2 entities) | 9 | $171 |
| Dexcom, Inc. | 5 | $94 |
| Radius Health, Inc. | 4 | $90 |
| Boehringer Ingelheim | 4 | $74 |
| Merck | 5 | $68 |
| Abbott | 4 | $66 |
| Antares Pharma, Inc. | 3 | $58 |
| Roche Diabetes Care, Inc. | 1 | $56 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Johnson & Johnson | 3 | $51 |
| Corcept Therapeutics | 2 | $51 |
| Shire North American Group Inc | 2 | $33 |
| IBSA Pharma Inc. | 2 | $33 |
| Mannkind Corporation | 2 | $32 |
| AbbVie | 2 | $29 |
| Insulet Corporation | 2 | $29 |
| Pfizer | 1 | $25 |
| Medtronic | 1 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Vivus LLC | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Lifescan, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,635 in reported general payments places this provider in the 55th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 42 | $310 |
| Calcitriol | 12 | $213 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Claremont
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.